Comparison of augmented Berlin-Frankfurt-Münster (BFM) and BFM 2000 treatment protocols in children diagnosed with high-risk acute lymphoblastic leukemia

Samet Özer; Fatma Leyla Ağaoğlu; Zeynep Karakaş; Ayşegül Ünüvar; Ömer Devecioğlu

Article Details

Comparison of augmented Berlin-Frankfurt-Münster (BFM) and BFM 2000 treatment protocols in children diagnosed with high-risk acute lymphoblastic leukemia

Authors:

Samet Özer | Fatma Leyla Ağaoğlu | Zeynep Karakaş | Ayşegül Ünüvar | Ömer Devecioğlu

Publisher:

Prusa Medical Publishing

Main Topics:

Pediatric Hematology and Oncology

Journal:

The European Research Journal Vol.10 Issue 5, pp.456-464

Document Type:

Article

Publication Date:

4/2024

Document Language:

English

Document ID (Org No.):

2001325104

pISSN:

2149-3189

Keywords:

Abstract:

 Objectives: The main purpose of this study is comparing the augmented Berlin-Frankfurt-Münster BFM and BFM 2000 treatment protocols applied to pediatric patients diagnosed with high-risk acute lymphoblastic leukemia ALL in our clinic in different years in terms of relapse incidence and survival rates. Methods: When evaluated all patients considering the Childrens Oncology Group COG criteria, 53 of our patients who were in the medium or high risk group according to the BFM 2000 protocol and were in the high risk group received treatment with Augmented BFM protocol and 17 of them received the BFM 2000 protocol. Age, gender, bone pathology, physical examination, hepatomegaly, splenomegaly, lymphadenopathy, presence of bleeding, hemogram values, immunophenotype, 8th, 14th and 33rd day treatment response, presence of translocation, central nervous system CNS, extramedullary involvement, risk group, presence of relapse, time to relapse, follow-up period and hospital stay until maintenance treatment were examined. Results: Event-Free Survival EFS and Overall Survival OS values of patients were 83.6 and 90.1, respectively. While EFS was 89.4 and OS was 90.6 in the group receiving the Augmented BFM treatment protocol, EFS was calculated as 71.7 and OS was 88.2 in those receiving the BFM-2000 treatment protocol. Accordingly, when the EFS values of those who received the Augmented BFM treatment protocol were compared with those who received BFM-2000, statistically significant values were found P0.01. Conclusions: It was observed that the augmented BFM treatment protocol was more protective against relapses and shortened the duration of hospitalization compared to the BFM 2000 treatment protocol.

 Objectives: The main purpose of this study is comparing the augmented Berlin-Frankfurt-Münster BFM and BFM 2000 treatment protocols applied to pediatric patients diagnosed with high-risk acute lymphoblastic leukemia ALL in our clinic in different years in terms of relapse incidence and survival rates. Methods: When evaluated all patients considering the Childrens Oncology Group COG criteria, 53 of our patients who were in the medium or high risk group according to the BFM 2000 protocol and were in the high risk group received treatment with Augmented BFM protocol and 17 of them received the BFM 2000 protocol. Age, gender, bone pathology, physical examination, hepatomegaly, splenomegaly, lymphadenopathy, presence of bleeding, hemogram values, immunophenotype, 8th, 14th and 33rd day treatment response, presence of translocation, central nervous system CNS, extramedullary involvement, risk group, presence of relapse, time to relapse, follow-up period and hospital stay until maintenance treatment were examined. Results: Event-Free Survival EFS and Overall Survival OS values of patients were 83.6 and 90.1, respectively. While EFS was 89.4 and OS was 90.6 in the group receiving the Augmented BFM treatment protocol, EFS was calculated as 71.7 and OS was 88.2 in those receiving the BFM-2000 treatment protocol. Accordingly, when the EFS values of those who received the Augmented BFM treatment protocol were compared with those who received BFM-2000, statistically significant values were found P0.01. Conclusions: It was observed that the augmented BFM treatment protocol was more protective against relapses and shortened the duration of hospitalization compared to the BFM 2000 treatment protocol.

 Objectives: The main purpose of this study is comparing the augmented Berlin-Frankfurt-Münster BFM and BFM 2000 treatment protocols applied to pediatric patients diagnosed with high-risk acute lymphoblastic leukemia ALL in our clinic in different years in terms of relapse incidence and survival rates. Methods: When evaluated all patients considering the Childrens Oncology Group COG criteria, 53 of our patients who were in the medium or high risk group according to the BFM 2000 protocol and were in the high risk group received treatment with Augmented BFM protocol and 17 of them received the BFM 2000 protocol. Age, gender, bone pathology, physical examination, hepatomegaly, splenomegaly, lymphadenopathy, presence of bleeding, hemogram values, immunophenotype, 8th, 14th and 33rd day treatment response, presence of translocation, central nervous system CNS, extramedullary involvement, risk group, presence of relapse, time to relapse, follow-up period and hospital stay until maintenance treatment were examined. Results: Event-Free Survival EFS and Overall Survival OS values of patients were 83.6 and 90.1, respectively. While EFS was 89.4 and OS was 90.6 in the group receiving the Augmented BFM treatment protocol, EFS was calculated as 71.7 and OS was 88.2 in those receiving the BFM-2000 treatment protocol. Accordingly, when the EFS values of those who received the Augmented BFM treatment protocol were compared with those who received BFM-2000, statistically significant values were found P0.01. Conclusions: It was observed that the augmented BFM treatment protocol was more protective against relapses and shortened the duration of hospitalization compared to the BFM 2000 treatment protocol.

 Objectives: The main purpose of this study is comparing the augmented Berlin-Frankfurt-Münster BFM and BFM 2000 treatment protocols applied to pediatric patients diagnosed with high-risk acute lymphoblastic leukemia ALL in our clinic in different years in terms of relapse incidence and survival rates. Methods: When evaluated all patients considering the Childrens Oncology Group COG criteria, 53 of our patients who were in the medium or high risk group according to the BFM 2000 protocol and were in the high risk group received treatment with Augmented BFM protocol and 17 of them received the BFM 2000 protocol. Age, gender, bone pathology, physical examination, hepatomegaly, splenomegaly, lymphadenopathy, presence of bleeding, hemogram values, immunophenotype, 8th, 14th and 33rd day treatment response, presence of translocation, central nervous system CNS, extramedullary involvement, risk group, presence of relapse, time to relapse, follow-up period and hospital stay until maintenance treatment were examined. Results: Event-Free Survival EFS and Overall Survival OS values of patients were 83.6 and 90.1, respectively. While EFS was 89.4 and OS was 90.6 in the group receiving the Augmented BFM treatment protocol, EFS was calculated as 71.7 and OS was 88.2 in those receiving the BFM-2000 treatment protocol. Accordingly, when the EFS values of those who received the Augmented BFM treatment protocol were compared with those who received BFM-2000, statistically significant values were found P0.01. Conclusions: It was observed that the augmented BFM treatment protocol was more protective against relapses and shortened the duration of hospitalization compared to the BFM 2000 treatment protocol.

Article Details

Comparison of augmented Berlin-Frankfurt-Münster (BFM) and BFM 2000 treatment protocols in children diagnosed with high-risk acute lymphoblastic leukemia

Authors:

Samet Özer | Fatma Leyla Ağaoğlu | Zeynep Karakaş | Ayşegül Ünüvar | Ömer Devecioğlu

Publisher:

Prusa Medical Publishing

Main Topics:

Pediatric Hematology and Oncology

Journal:

The European Research Journal Vol.10 Issue 5, pp.456-464

Document Type:

Article

Publication Date:

4/2024

Document Language:

English

Document ID (Org No.):

2001325104

pISSN:

2149-3189

Acute lymphoblastic leukemia

child

treatment protocol

Issues

Article Details

Comparison of augmented Berlin-Frankfurt-Münster (BFM) and BFM 2000 treatment protocols in children diagnosed with high-risk acute lymphoblastic leukemia

Authors: Samet Özer | Fatma Leyla Ağaoğlu | Zeynep Karakaş | Ayşegül Ünüvar | Ömer Devecioğlu

Publisher: Prusa Medical Publishing

Main Topics: Pediatric Hematology and Oncology

Journal: The European Research Journal Vol.10 Issue 5, pp.456-464

Document Type: Article

Publication Date: 4/2024

Document Language: English

Document ID (Org No.): 2001325104

pISSN: 2149-3189

Acute lymphoblastic leukemia

child

treatment protocol

Issues

Authors:

Samet Özer | Fatma Leyla Ağaoğlu | Zeynep Karakaş | Ayşegül Ünüvar | Ömer Devecioğlu

Publisher:

Prusa Medical Publishing

Main Topics:

Pediatric Hematology and Oncology

Journal:

The European Research Journal Vol.10 Issue 5, pp.456-464

Document Type:

Article

Publication Date:

4/2024

Document Language:

English

Document ID (Org No.):

2001325104

pISSN:

2149-3189